ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,537.02
      0.51%
      US Tech 100
      19,641.60
      0.83%
      Dow Jones
      39,308.00
      -0.06%
      Brent Oil
      86.915
      -0.48%
      Bitcoin
      55,323.37
      -2.94%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Immutep Ltd (IMMP)

      7. Immutep Ltd (IMMP) News

      IMMP

      Immutep (IMMP)

      Immutep Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IMMP
      DateTimeSourceHeadlineSymbolCompany
      10/16/20238:00AMGlobeNewswire Inc.Immutep Announces Publication of Abstracts at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
      10/03/20238:00AMGlobeNewswire Inc.Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
      09/21/20238:00AMGlobeNewswire Inc.Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseNASDAQ:IMMPImmutep Ltd
      09/05/20239:00AMGlobeNewswire Inc.Immutep to Participate in September Investor ConferencesNASDAQ:IMMPImmutep Ltd
      08/01/20238:00AMGlobeNewswire Inc.Immutep Receives Positive Scientific Advice from European Medicines AgencyNASDAQ:IMMPImmutep Ltd
      07/31/20238:00AMGlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY23NASDAQ:IMMPImmutep Ltd
      07/31/20238:00AMGlobeNewswire Inc.Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
      07/28/20238:00AMGlobeNewswire Inc.First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
      07/28/20236:31AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
      06/28/20236:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      06/27/20238:00AMGlobeNewswire Inc.Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway InhibitorNASDAQ:IMMPImmutep Ltd
      06/27/20238:00AMGlobeNewswire Inc.Immutep Completes A$80 Million Capital RaiseNASDAQ:IMMPImmutep Ltd
      06/21/20236:05AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      06/20/20238:00AMGlobeNewswire Inc.Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3NASDAQ:IMMPImmutep Ltd
      06/07/20238:00AMGlobeNewswire Inc.Immutep to Participate at the Jefferies Healthcare ConferenceNASDAQ:IMMPImmutep Ltd
      06/06/20236:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      06/05/20238:00AMGlobeNewswire Inc.Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
      06/05/20236:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      06/02/20238:00AMGlobeNewswire Inc.Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement OfferNASDAQ:IMMPImmutep Ltd
      05/31/20236:03AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      05/29/20238:00AMGlobeNewswire Inc.Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology StudyNASDAQ:IMMPImmutep Ltd
      05/26/20238:00AMGlobeNewswire Inc.Immutep Announces Publication of Abstracts for ASCO 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
      05/25/20238:00AMGlobeNewswire Inc.Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
      05/25/20236:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      05/24/20238:00AMGlobeNewswire Inc.Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 TrialNASDAQ:IMMPImmutep Ltd
      05/17/20238:00AMGlobeNewswire Inc.Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
      05/17/20236:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      05/16/20238:00AMGlobeNewswire Inc.Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
      05/16/20236:10AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
      05/09/20238:00AMGlobeNewswire Inc.Immutep to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:IMMPImmutep Ltd
       Showing the most relevant articles for your search:NASDAQ:IMMP